期刊文献+

Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections 被引量:24

Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections
在线阅读 下载PDF
导出
摘要 The yeast Saccharomyces boulardii CNCM I-745 is one of the probiotics recommended for the prevention of antibiotic-associated diarrhea. Studies conducted in vivo and in vitro demonstrated that in the case of infectious diseases there are two potential sites of action of Saccharomyces boulardii CNCM I-745:(1)An action on enteropathogenic microorganisms(adhesion of bacteria and their elimination or an effect on their virulence factors: Toxins, lipopolysaccharide,etc.); and(2) a direct action on the intestinal mucosa(trophic effects, effects on epithelial reconstitution, anti-secretory effects, anti-inflammatory,immunomodulators). Oral administration of Saccharomyces boulardii CNCM I-745 to healthy subjects does not alter their microbiota. However, in the case of diseases associated with the use of antibiotics or chronic diarrhea, Saccharomyces boulardii CNCM I-745 can restore the intestinal microbiota faster. The interaction of Saccharomyces boulardii CNCM I-745 with the innate immune system have been recently demonstrated thus opening up a new therapeutic potential of this yeast in the case of diseases associated with intestinal infections but also other pathologies associated with dysbiosis such as inflammatory diseases. The yeast Saccharomyces boulardii CNCM I-745 is one of the probiotics recommended for the prevention of antibiotic-associated diarrhea. Studies conducted in vivo and in vitro demonstrated that in the case of infectious diseases there are two potential sites of action of Saccharomyces boulardii CNCM I-745:(1)An action on enteropathogenic microorganisms(adhesion of bacteria and their elimination or an effect on their virulence factors: Toxins, lipopolysaccharide,etc.); and(2) a direct action on the intestinal mucosa(trophic effects, effects on epithelial reconstitution, anti-secretory effects, anti-inflammatory,immunomodulators). Oral administration of Saccharomyces boulardii CNCM I-745 to healthy subjects does not alter their microbiota. However, in the case of diseases associated with the use of antibiotics or chronic diarrhea, Saccharomyces boulardii CNCM I-745 can restore the intestinal microbiota faster. The interaction of Saccharomyces boulardii CNCM I-745 with the innate immune system have been recently demonstrated thus opening up a new therapeutic potential of this yeast in the case of diseases associated with intestinal infections but also other pathologies associated with dysbiosis such as inflammatory diseases.
出处 《World Journal of Gastroenterology》 SCIE CAS 2019年第18期2188-2203,共16页 世界胃肠病学杂志(英文版)
关键词 SACCHAROMYCES boulardii CNCM I-745 PROBIOTICS YEAST INTESTINAL INFECTION Mechanism Saccharomyces boulardii CNCM I-745 Probiotics Yeast Intestinal infection Mechanism
作者简介 Corresponding author:Dorota Czerucka,PhD,Senior Researcher,Senior Scientist,Department of Human Health,Division of Ecosystems and Immunity,Center Scientific of Monaco,8 Quai Antoine 1er,Monaco MC98000,Monaco. dczerucka@centrescientifique.mc Telephone:+212-377-97774435 Fax:+212-377-98988674.
  • 相关文献

参考文献1

二级参考文献15

  • 1S.M. Schneider,P. Le Gall,F. Girard-Pipau,T. Piche,A. Pompei,J.-L. Nano,X. Hébuterne,P. Rampal.Total artificial nutrition is associated with major changes in the fecal flora[J].European Journal of Nutrition.2000(6)
  • 2Mario Guslandi,Gianni Mezzi,Massimo Sorghi,Pier Alberto Testoni.Saccharomyces boulardii in Maintenance Treatment of Crohn’s Disease[J].Digestive Diseases and Sciences.2000(7)
  • 3G. Bleichner,H. Bléhaut,H. Mentec,D. Moyse.Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients[J].Intensive Care Medicine.1997(5)
  • 4S. Adam,S. Batson.A study of problems associated with the delivery of enteral feed in critically ill patients in five ICUs in the UK[J].Intensive Care Medicine.1997(3)
  • 5G. W. Welling Ph. D.,Geke J. Meijer-Severs M. S.,Gé Helmus,Edith Santen,R. H. J. Tonk,Hilly G. Vries- Hospers M. D., Ph. D.,D. Waaij M. D., Ph. D.The effect of ceftriaxone on the anaerobic bacterial flora and the bacterial enzymatic activity in the intestinal tract[J].Infection.1991(5)
  • 6Rolfe RD.Role of volatile fatty acids in colonization resistance to Clostridium difficile[].Infection and Immunity.1984
  • 7Meijer-Severs GJ,Van Santen E,Meijer BC.Short-chain fatty acid and organic acid concentrations in feces of healthy human volunteers and their correlations with anaerobe cultural counts during systemic ceftriaxone administration[].Scandinavian Journal of Gastroenterology.1990
  • 8Weaver GA,Krause JA,Miller TL,Wolin MJ.Short chain fatty acid distributions of enema samples from a sigmoidoscopy population: an association of high acetate and low butyrate ratios with adenomatous polyps and colon cancer[].Gut.1988
  • 9Cummings JH,Macfarlane GT.Role of intestinal bacteria in nutrient metabolism[].Clinical Nutrition.1997
  • 10Hopkins M,Sharp R,Macfarlane G.Age and disease-related changes in intestinal bacterial populations assessed by cell culture, 16S-rRNA abundance, and community cellular fatty acid profiles[].Gut.2001

共引文献32

同被引文献220

引证文献24

二级引证文献132

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部